| [1] |
Thio CL, Guo N, Xie C, et al. Global elimination of mother-to-child transmission of hepatitis B: revisiting the current strategy. Lancet Infect Dis, 2015, 15:981-985.
|
| [2] |
Aba HO, Aminu M. Seroprevalence of hepatitis B virus serological markers among pregnant Nigerian women. Ann Afr Med, 2016, 15:20-27.
|
| [3] |
Xu Y, Liu H, Wang Y, et al. The next step in controlling HBV in China. BMJ, 2013, 347:f4503.
|
| [4] |
Tran TT, Ahn J, Reau NS. ACG Clinical Guideline: Liver Disease and Pregnancy. Am J Gastroenterol, 2016, 111:176-194; quiz 196.
|
| [5] |
Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int, 2016, 10:1-98.
|
| [6] |
Ma L, Alla NR, Li X, et al. Mother-to-child transmission of HBV: review of current clinical management and prevention strategies. Rev Med Virol, 2014, 24:396-406.
|
| [7] |
Gentile I, Borgia G. Vertical transmission of hepatitis B virus: challenges and solutions. Int J Womens Health, 2014, 6:605-611.
|
| [8] |
Xu YY, Liu HH, Zhong YW, et al. Peripheral blood mononuclear cell traffic plays a crucial role in mother-to-infant transmission of hepatitis B virus. Int J Biol Sci, 2015, 11:266-273.
|
| [9] |
Yu M, Jiang Q, Gu X, et al. Correlation between vertical transmission of hepatitis B virus and the expression of HBsAg in ovarian follicles and placenta. PLoS One, 2013, 8:e54246.
|
| [10] |
Jin L, Nie R, Li Y, et al. Hepatitis B surface antigen in oocytes and embryos may not result in vertical transmission to offspring of hepatitis B virus carriers. Fertil Steril, 2016, 105:1010-1013.
|
| [11] |
Zhang Z, Li A, Xiao X. Risk factors for intrauterine infection with hepatitis B virus. Int J Gynaecol Obstet, 2014, 125:158-161.
|
| [12] |
Lu LL, Chen BX, Wang J, et al. Maternal transmission risk and antibody levels against hepatitis B virus e antigen in pregnant women. Int J Infect Dis, 2014, 28:41-44.
|
| [13] |
Cui AM, Cheng XY, Shao JG, et al. Maternal hepatitis B virus carrier status and pregnancy outcomes: a prospective cohort study. BMC Pregnancy Childbirth, 2016, 16:87.
|
| [14] |
Safir A, Levy A, Sikuler E, et al. Maternal hepatitis B virus or hepatitis C virus carrier status as an independent risk factor for adverse perinatal outcome. Liver Int, 2010, 30:765-770.
|
| [15] |
Liu J, Bi Y, Xu C, et al. Kinetic Changes of Viremia and Viral Antigens of Hepatitis B Virus During and After Pregnancy. Medicine (Baltimore), 2015, 94:e2001.
|
| [16] |
Elefsiniotis I, Vezali E, Vrachatis D, et al. Post-partum reactivation of chronic hepatitis B virus infection among hepatitis B e-antigen-negative women. World J Gastroenterol, 2015, 21:1261-1267.
|
| [17] |
Goyal A, Murray JM. The impact of vaccination and antiviral therapy on hepatitis B and hepatitis D epidemiology. PLoS One, 2014, 9:e110143.
|
| [18] |
Jin H, Zhao Y, Tan Z, et al. Immunization interventions to interrupt hepatitis B virus mother-to-child transmission: a meta-analysis of randomized controlled trials. BMC Pediatr, 2014, 14:307.
|
| [19] |
Komatsu H. Hepatitis B virus: where do we stand and what is the next step for eradication? World J Gastroenterol, 2014, 20:8998-9016.
|
| [20] |
Kunoee A, Nielsen J, Cowan S. Hepatitis B vaccination coverage and risk factors associated with incomplete vaccination of children born to hepatitis B surface antigen-positive mothers, Denmark, 2006 to 2010. Euro Surveill, 2016, 21:pii=30136.
|
| [21] |
Liu J, Feng Y, Wang J, et al. An "immune barrier" is formed in the placenta by hepatitis B immunoglobulin to protect the fetus from hepatitis B virus infection from the mother. Hum Vaccin Immunother, 2015, 11:2068-2076.
|
| [22] |
Zhang L, Gui X, Wang B, et al. A study of immunoprophylaxis failure and risk factors of hepatitis B virus mother-to-infant transmission. Eur J Pediatr, 2014, 173:1161-1168.
|
| [23] |
Kang W, Ding Z, Shen L, et al. Risk factors associated with immunoprophylaxis failure against mother to child transmission of hepatitis B virus and hepatitis B vaccination status in Yunnan province, China. Vaccine, 2014, 32:3362-3366.
|
| [24] |
中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015更新版). 肝脏, 2015, 20:915-932.
|
| [25] |
Wu Q, Huang H, Sun X, et al. Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long-term study. Clin Gastroenterol Hepatol, 2015, 13:1170-1176.
|
| [26] |
Yu MM, Jiang Q, Ji Y, et al. Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus. J Clin Virol, 2014, 61:55-60.
|
| [27] |
Pan CQ, Duan Z, Dai E, et al. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. N Engl J Med, 2016, 374:2324-2334.
|
| [28] |
Nguyen V, Tan PK, Greenup AJ, et al. Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare. Aliment Pharmacol Ther, 2014, 39:1225-1234.
|
| [29] |
Samadi Kochaksaraei G, Castillo E, Osman M, et al. Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region. J Viral Hepat, 2016, 23:15-22.
|
| [30] |
Chen HL, Lee CN, Chang CH, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology, 2015, 62:375-386.
|
| [31] |
Greenup AJ, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol, 2014, 61:502-507.
|
| [32] |
Wang J, Liu J, Qi C, et al. Efficacy of tenofovir disoproxil fumarate to prevent vertical transmission in mothers with lamivudine-resistant HBV. Antivir Ther, 2015, 20:681-687.
|
